Cantor Fitzgerald Analysts Give Applied Genetic Technologies Corporation (AGTC) a $9.00 Price Target

Cantor Fitzgerald set a $9.00 target price on Applied Genetic Technologies Corporation (NASDAQ:AGTC) in a report issued on Friday morning. The brokerage currently has a hold rating on the biotechnology company’s stock.

“Natural history data from imaging 41 patients with CNGB3-associated achromatopsia (ACHM B3) between 6 and 26 months was published in the journel Retina journal today, suggest functional endpoints for evaluating efficacy.”,” Cantor Fitzgerald’s analyst commented.

Other research analysts also recently issued reports about the company. HC Wainwright set a $16.00 target price on Applied Genetic Technologies Corporation and gave the stock a buy rating in a research note on Saturday, June 10th. Stifel Nicolaus dropped their target price on Applied Genetic Technologies Corporation from $15.00 to $12.00 and set a buy rating on the stock in a research note on Thursday, September 14th. Zacks Investment Research upgraded Applied Genetic Technologies Corporation from a sell rating to a hold rating in a research note on Tuesday, July 25th. BMO Capital Markets restated an outperform rating and set a $7.00 target price (down from $14.00) on shares of Applied Genetic Technologies Corporation in a research note on Thursday, September 14th. Finally, ValuEngine downgraded Applied Genetic Technologies Corporation from a hold rating to a sell rating in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $11.71.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) opened at 4.00 on Friday. Applied Genetic Technologies Corporation has a one year low of $3.50 and a one year high of $10.85. The stock’s 50 day moving average price is $4.22 and its 200-day moving average price is $5.17. The company has a market capitalization of $72.35 million, a P/E ratio of 200.00 and a beta of 1.63.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last announced its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.40). Applied Genetic Technologies Corporation had a return on equity of 1.45% and a net margin of 4.28%. The business had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $12.39 million. During the same quarter last year, the firm earned $0.15 earnings per share. The firm’s quarterly revenue was down 31.4% compared to the same quarter last year. Equities analysts forecast that Applied Genetic Technologies Corporation will post ($0.81) EPS for the current year.

WARNING: “Cantor Fitzgerald Analysts Give Applied Genetic Technologies Corporation (AGTC) a $9.00 Price Target” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://ledgergazette.com/2017/10/09/cantor-fitzgerald-analysts-give-applied-genetic-technologies-corporation-agtc-a-9-00-price-target.html.

Institutional investors and hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd acquired a new stake in Applied Genetic Technologies Corporation during the 1st quarter worth about $123,000. Wells Fargo & Company MN lifted its position in Applied Genetic Technologies Corporation by 1.1% during the 1st quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 200 shares during the period. Trexquant Investment LP lifted its position in Applied Genetic Technologies Corporation by 3.2% during the 2nd quarter. Trexquant Investment LP now owns 20,000 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 611 shares during the period. Teachers Advisors LLC lifted its position in Applied Genetic Technologies Corporation by 13.1% during the 4th quarter. Teachers Advisors LLC now owns 22,692 shares of the biotechnology company’s stock worth $212,000 after acquiring an additional 2,632 shares during the period. Finally, Credit Suisse AG lifted its position in Applied Genetic Technologies Corporation by 10.9% during the 1st quarter. Credit Suisse AG now owns 27,110 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 2,662 shares during the period. 54.66% of the stock is owned by institutional investors.

About Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Analyst Recommendations for Applied Geneti


<div style=

“Natural history data from imaging 41 patients with CNGB3-associated achromatopsia (ACHM B3) between 6 and 26 months was published in the journel Retina journal today, suggest functional endpoints for evaluating efficacy.”,” Cantor Fitzgerald’s analyst commented.

Other research analysts also recently issued reports about the company. HC Wainwright set a $16.00 target price on Applied Genetic Technologies Corporation and gave the stock a buy rating in a research note on Saturday, June 10th. Stifel Nicolaus dropped their target price on Applied Genetic Technologies Corporation from $15.00 to $12.00 and set a buy rating on the stock in a research note on Thursday, September 14th. Zacks Investment Research upgraded Applied Genetic Technologies Corporation from a sell rating to a hold rating in a research note on Tuesday, July 25th. BMO Capital Markets restated an outperform rating and set a $7.00 target price (down from $14.00) on shares of Applied Genetic Technologies Corporation in a research note on Thursday, September 14th. Finally, ValuEngine downgraded Applied Genetic Technologies Corporation from a hold rating to a sell rating in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $11.71.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) opened at 4.00 on Friday. Applied Genetic Technologies Corporation has a one year low of $3.50 and a one year high of $10.85. The stock’s 50 day moving average price is $4.22 and its 200-day moving average price is $5.17. The company has a market capitalization of $72.35 million, a P/E ratio of 200.00 and a beta of 1.63.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last announced its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.40). Applied Genetic Technologies Corporation had a return on equity of 1.45% and a net margin of 4.28%. The business had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $12.39 million. During the same quarter last year, the firm earned $0.15 earnings per share. The firm’s quarterly revenue was down 31.4% compared to the same quarter last year. Equities analysts forecast that Applied Genetic Technologies Corporation will post ($0.81) EPS for the current year.

WARNING: “Cantor Fitzgerald Analysts Give Applied Genetic Technologies Corporation (AGTC) a $9.00 Price Target” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://ledgergazette.com/2017/10/09/cantor-fitzgerald-analysts-give-applied-genetic-technologies-corporation-agtc-a-9-00-price-target.html.

Institutional investors and hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd acquired a new stake in Applied Genetic Technologies Corporation during the 1st quarter worth about $123,000. Wells Fargo & Company MN lifted its position in Applied Genetic Technologies Corporation by 1.1% during the 1st quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 200 shares during the period. Trexquant Investment LP lifted its position in Applied Genetic Technologies Corporation by 3.2% during the 2nd quarter. Trexquant Investment LP now owns 20,000 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 611 shares during the period. Teachers Advisors LLC lifted its position in Applied Genetic Technologies Corporation by 13.1% during the 4th quarter. Teachers Advisors LLC now owns 22,692 shares of the biotechnology company’s stock worth $212,000 after acquiring an additional 2,632 shares during the period. Finally, Credit Suisse AG lifted its position in Applied Genetic Technologies Corporation by 10.9% during the 1st quarter. Credit Suisse AG now owns 27,110 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 2,662 shares during the period. 54.66% of the stock is owned by institutional investors.

About Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Analyst Recommendations for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.